PETROCHINA
00857
ABC
01288
CHINA SHENHUA
01088
BANKCOMM
03328
KB LAMINATES
01888
HK Stock MarketDetailed Quotes
02225 JINHAI MED-NEW
- 1.620
- -0.340-17.35%
Market Closed Jan 3 16:08 CST
8.38BMarket Cap-147.27P/E (TTM)
1.930High1.610Low3.21MVolume1.900Open1.960Pre Close5.70MTurnover0.06%Turnover RatioLossP/E (Static)5.17BShares2.36052wk High38.57P/B8.38BFloat Cap0.19552wk Low--Dividend TTM5.17BShs Float2.360Historical High--Dividend LFY16.33%Amplitude0.124Historical Low1.776Avg Price5000Lot Size--Div YieldTTM--Div Yield LFY
JINHAI MED-NEW News
Now Health Medical (02225): Partnering with Sinopharm Ling Commerce to accelerate the commercialization process of high-end medical instruments.
Jinhai Medical Fabric announced that its subsidiary Jinhai Xiehuan Medical has reached a commercial cooperation with Sinopharm Lingbing, authorizing Sinopharm Lingbing as the exclusive distributor of the company's high-end medical instruments in China.
Jinhai Medical Technology's Unit Authorizes Sinopharm to Solely Distribute Medical Devices in China
JINHAI MED TECH (02225.HK) has signed a master sales agreement with China National Pharmaceutical Group.
On January 3, Gelonghui reported that JINHAI MED TECH (02225.HK) announced that its wholly-owned subsidiary Shanghai JINHAI Xiehuan Medical Technology Co., Ltd. ("JINHAI Xiehuan") has recently entered into a total sales agreement with SINOPHARM Lingshang Hospital Management Service (Shanghai) Co., Ltd. ("SINOPHARM Lingshang"). According to this agreement, JINHAI Xiehuan authorizes SINOPHARM Lingshang as the exclusive distributor for several high-end medical instruments of the group in China, valid until October 2025. SINOPHARM Lingshang is a joint venture established by SINOPHARM and Mitsubishi Corporation of Japan. As a comprehensive operation service provider for medical consumables, SINOPHARM.
JINHAI MED TECH (02225.HK) has authorized Sinopharm Ling Shang as the exclusive distributor of several high-end medical instruments in China.
JINHAI MED TECH (02225.HK) announced that its wholly-owned subsidiary JINHAI XIEHUI recently entered into a total sales agreement with China National Pharmaceutical Group Logistics. According to this agreement, JINHAI XIEHUI authorized China National Pharmaceutical Group Logistics as the exclusive distributor of certain high-end medical instruments in China, valid until October of this year.
Jinhai Medical Resolves High Shareholding Concentration
JINHAI MED TECH (02225.HK) does not have its shares concentrated in a few Shareholders.
Gelonghui, December 31 | JINHAI MED TECH (02225.HK) announced that the company believes that the concerns regarding the High Ownership situation mentioned in the CSRC announcement no longer exist as of December 9, 2024. The High Ownership situation referred to in the CSRC announcement should not be used as a basis for evaluating the current state of the company's ownership structure. The Board of Directors believes that, based on the analysis results, (i) the High Ownership situation of the company mentioned in the CSRC announcement on November 20, 2024, no longer exists as of December 9, 2024; and (ii) the company's ownership is not concentrated among a very small number of Shareholders.
Jinhai Medical Technology Forms Nomination Committee for Board
Jinhai International's New Remuneration Committee for Transparency
Jinhai Medical Technology to Move Headquarters to China
Today, Honghai Medical (02225) was awarded the Golden Hong Kong Stock "Most Valuable Pharmaceutical and Medical Company", with annual highlights frequently emerging.
At the "9th Zhito Finance Capital Markets Annual Conference and Award Ceremony for Listed Companies", Jin Hai Medical was awarded the honor of "Most Valuable Medical and Healthcare Company".
SFC Finds High Concentration of Shareholding in Jinhai Medical Technology, Unusual Share Price Movement
Jinhai Medical's High Shareholding Concentration Raises Volatility Concerns
Jinhai med tech (02225.HK) has a highly concentrated ownership.
On December 9, Gelonghui reported that jinhai med tech (02225.HK) announced that the China Securities Regulatory Commission recently inquired about the company's shareholding distribution. The inquiry results showed that as of November 20, 2024, there are twenty-seven shareholders and their related parties collectively holding 0.53328 billion shares of the company, accounting for 41.26% of the company's issued share capital. This shareholding together with the 0.6325 billion shares held by the company’s chairman and executive director (which accounts for 48.94% of the issued share capital) amounts to 90.20% of the company's issued share capital. Therefore, the company has only 0.12672 billion shares.
Today, Haichang Medical (02225) attended the AI Minimally Invasive Field Technology Development Seminar to explore the new future of AI Minimally Invasive Field together.
On November 28th, a seminar with the theme of "Technological Development of AI in the Minimally Invasive Field" was successfully held in Shanghai. As an important academic conference in the domestic minimally invasive AI field, Chairman Chen Guobao of Jinhai Med Tech (02225) attended the conference together with the group's core members.
Leading innovation in medical instruments! Jin Hai Medical (02225) has been honored on the 2024 "Top 10 Qipu Seed List".
Shanghai's jinhai med tech Co., Ltd. (02225) has ranked in the '2024 medical instruments innovative Qipu Seed List TOP10' with the project '4K naked-eye 3D fluorescent asia vets navigation endoscope system'.
Jinhai Medical Technology Plans Share Subdivision
Hong Kong stock market anomaly | jinhai med tech (02225) surged by over 6%, making many important breakthroughs in the endoscopy field, doubling its profit growth in the first half of the year.
jinhai med tech (02225) surged by over 6%, as of the deadline for submission, it rose by 4.1%, closing at 6.35 Hong Kong dollars, with a turnover of 8.5101 million Hong Kong dollars.
JINHAI MED TECH To Carry Out 4-for-1 Stock Split On December 12th, 2024
November 2nd (Beijing Time) - $JINHAI MED TECH(02225.HK)$ is about to implement a 4-for-1 stock split of shares. The shares will begin trading on a split-adjusted basis from December 12th, 2024.$
jinhai med tech (02225.HK) recommends a one-for-four stock split with a maintenance of 5,000 shares per board lot
jinhai med tech (02225.HK) stated that the board of directors proposed to split the company's share capital into four shares per share with a nominal value of 0.25 Hong Kong cents per share for both issued and unissued shares. Currently, the shares are traded in units of 5,000 shares per transaction. After the split, the units for trading will remain at 5,000 shares of split shares per transaction.
jinhai med tech (02225) plans a 1 for 4 stock split.
jinhai med tech (02225) announced that the board of directors recommends splitting the existing nominal value of HK$0.01 per share in the company's share capital...
Trending HK Stocks
HK Dividend Stocks HK Dividend Stocks
Dividend stocks are stocks of companies in the HK stock market that regularly distribute dividends to shareholders, generally representing stable businesses. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in HK dividend stocks, ranked from highest to lowest based on real-time market data. Dividend stocks are stocks of companies in the HK stock market that regularly distribute dividends to shareholders, generally representing stable businesses. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in HK dividend stocks, ranked from highest to lowest based on real-time market data.